Management ChangeJul 6, 2026, 08:02 AM
Corbus Pharma Appoints Leonardo Viana Nicacio, M.D., as CMO
AI Summary
Corbus Pharmaceuticals Holdings, Inc. announced the appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer. Dr. Nicacio brings over 20 years of experience in solid tumor drug development, including his work on the antibody drug conjugate TIVDAK®. The company also highlighted upcoming milestones, including the planned initiation of the TEMPO-1 registrational study for CRB-701 in 2L oropharyngeal squamous cell carcinoma this summer, and data readouts for CRB-913 in obesity and CRB-701 in 1L OPSCC.
Key Highlights
- Corbus Pharmaceuticals appointed Leonardo Viana Nicacio, M.D., as Chief Medical Officer.
- Dr. Nicacio has over 20 years of pharmaceutical industry experience, including solid tumor drug development.
- He played a pivotal role in advancing the ADC TIVDAK® for metastatic cervical cancer.
- Corbus expects to initiate TEMPO-1 registrational study of CRB-701 in 2L OPSCC in summer 2026.
- Topline findings from CANYON-1 obesity study of CRB-913 are expected in late summer 2026.
- Anticipated data readout of CRB-701 in 1L OPSCC is planned for early 2027.
- CRB-701 has received two Fast Track designations from the FDA for HNSCC and cervical cancer.
Price Impact
More from CRBP